INS and COVID-19: The report of higher mortality in uncontrolled hyperglycemia patients reported by Bode et al. [23] and the fact that SARS coronavirus binds to pancreatic ACE2 receptors, decreases insulin secretion and causes b-cell dysfunction [24] lead to a valid speculation that uncontrolled hyperglycemia above 180 mg/dL in COVID-19 patients could be a marker of a very severe state.